STOCK TITAN
  1. Home
  2. News
  3. ANAB

AnaptysBio Inc - ANAB STOCK NEWS

Welcome to our dedicated news page for AnaptysBio (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on AnaptysBio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AnaptysBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AnaptysBio's position in the market.

News
Actym Therapeutics Appoints Thomas Smart as CEO
Rhea-AI Summary
Actym Therapeutics, a company focusing on a new drug modality for treating solid tumors, appoints Thomas Smart as the Chief Executive Officer. With 25 years of experience in the biopharmaceutical industry, Mr. Smart brings expertise in corporate development, strategic planning, and R&D translation. His appointment comes as Actym gears up for the clinical evaluation of its lead candidate, ACTM-838, showcasing a novel approach through the STACT platform at upcoming conferences. Smart's leadership aims to drive corporate growth, expand the pipeline, and maximize the therapeutic potential of ACTM-838.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
management
-
News
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
AnaptysBio, Inc. reports operating results for Q4 and year-end 2023, with cash and investments of $417 million and plans for ongoing clinical trials and new IND filings. The company aims to bring transformational medicines for autoimmune and inflammatory diseases, with top-line data expected for various trials by 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
earnings
-
News
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) announces participation in investor conference and medical meeting to present preclinical data on ANB032 for atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
News
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) announces the participation of its CEO, Daniel Faga, in Guggenheim’s 6th Annual Biotechnology Conference. The event will feature a fireside chat and a live webcast, providing investors with an opportunity to engage with the company's leadership and gain insights into its innovative immunology therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
News
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio from Centessa Pharmaceuticals (CNTA). Anaptys anticipates filing an IND application for the lead asset ANB101 in H2 2024. The company reiterates year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
News
Anaptys Named a BioSpace 2024 Best Places to Work Winner
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) Named BioSpace 2024 Best Place to Work for Second Consecutive Year
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
none
News
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
AnaptysBio, Inc. has initiated a global Phase 2b trial for rheumatoid arthritis (RA) treatment with rosnilimab. They are also starting a Phase 2 trial for ulcerative colitis (UC) treatment with rosnilimab. The company announced positive Phase 3 trial results for imsidolimab in generalized pustular psoriasis (GPP). They expect to have a cash runway through year-end 2026 and anticipate having $400 to $410 million in cash and investments by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.21%
Tags
earnings
-
News
Anaptys Announces Participation in November Investor Conferences
Rhea-AI Summary
AnaptysBio, a clinical-stage biotechnology company, announced its participation in multiple investor conferences in November. The conferences include Guggenheim 5th Annual I&I Conference, UBS Biopharma Conference 2023, Stifel 2023 Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and Evercore ISI 6th Annual HealthCONx Conference. Live webcasts of fireside chats will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
-
News
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Rhea-AI Summary
AnaptysBio to present at the 32nd EADV Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences clinical trial
News
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Rhea-AI Summary
AnaptysBio to host virtual R&D event on rosnilimab
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
Stock ANAB logo
AnaptysBio Inc

Nasdaq:ANAB

ANAB Rankings

#2959 Ranked by Market Cap
#4457 Ranked by Stock Gains
N/A Ranked by Dividends

ANAB Stock Data

571.12M
14.73M
0.4%
113.55%
16.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ANAB

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c